Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2023-02-28 · accession 0001209191-23-014872 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-02 | 2023-02-28 | KPTI | Poulton Stuart | EVP, Chief Development Off | A - Grant | $0.00 | +95.0K | 159.1K | +148% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-28 | A | A | 95,000 | $0.00 | 159,131 | D | — | — | (F1) Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024. |